Beryl Drugs share news, announcements and annual reports
BSE: 524606Pharmaceuticals & BiotechnologySmall Cap
Share price at the BSE close on 29 Oct 2026. Previous close ₹25.85.
29 Oct: open ₹25.72, high ₹25.72, low ₹23.20
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹13 Cr4,587th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 20.30
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 1.28
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 6.4%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 3.1%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.24
- Volume, BSEVolume. Shares traded on the last trading day. Volume in the glossary
- 1,477
Beryl Drugs has 572 announcements on record, routine notices left out; 1 in the 30 days to 30 Oct 2026, the latest on 7 Oct 2026.
Last results date
The last board meeting held for results; the company has not yet given notice of the next.Beryl Drugs quarterly results
The board met on 11 Aug 2026 to consider quarterly results
Notice filed 5 Aug 2026
Beryl Drugs annual reports, presentations and earnings calls
The company's own documents, latest first.Beryl Drugs financials, year by year
Annual reports28
- Annual report, year to Mar 20263 Sep 2026
- Annual report, year to Mar 20253 Sep 2025
- Annual report, year to Mar 20244 Sep 2024
- Annual report, year to Mar 202328 Aug 2023
- Annual report, year to Mar 20223 Sep 2022
23 earlier reports
- Annual report, year to Mar 20213 Sep 2021
- Annual report, year to Mar 20201 Dec 2020
- Annual report, year to Mar 20195 Sep 2019
- Annual report, year to Mar 20181 Oct 2018
- Annual report, year to Mar 201730 Aug 2017
- Annual report, year to Mar 201628 Aug 2016
- Annual report, year to Mar 20154 Sep 2015
- Annual report, year to Mar 20148 Sep 2014
- Annual report, year to Mar 20133 Sep 2013
- Annual report, year to Mar 20124 Sep 2012
- Annual report, year to Mar 201122 Dec 2011
- Annual report, year to Mar 2010Filing day not known
- Annual report, year to Mar 2009Filing day not known
- Annual report, year to Mar 2008Filing day not known
- Annual report, year to Mar 2007Filing day not known
- Annual report, year to Mar 2004Filing day not known
- Annual report, year to Mar 2003Filing day not known
- Annual report, year to Mar 2002Filing day not known
- Annual report, year to Mar 2001Filing day not known
- Annual report, year to Mar 2000Filing day not known
- Annual report, year to Mar 1999Filing day not known
- Annual report, year to Mar 1998Filing day not known
- Annual report, year to Mar 1997Filing day not known
Beryl Drugs share news and announcements
Newest first. Page 1 of 12.
Oct 2026
7 Oct · Compliance-57 (5) : intimation after the end of quarter
Sep 2026
29 Sep · Meeting
29 Sep · Approval For Increase In The Limit Of Material Related Party Transactions With M/S. Aminova Infusions Pvt. Ltd.
29 Sep · Meeting
3 Sep · Meeting
3 Sep · Meeting
3 Sep · Meeting
2 Sep · Corporate action
2 Sep · Board meeting
Aug 2026
27 Aug · Board meeting
Meeting on 2 Sep 2026: annual general meeting11 Aug · Results
5 Aug · Board meeting
Meeting on 11 Aug 2026: quarterly results
Jul 2026
21 Jul · Intimation Regarding Temporary Unavailability Of The Company's Website Due To An Unexpected Technical Issue
6 Jul · Compliance-57 (5) : intimation after the end of quarter
Jun 2026
16 Jun · Announcement under Regulation 30 (LODR)-Change in Registered Office Address
16 Jun · Board meeting
8 Jun · Board meeting
Meeting on 16 Jun 2026
May 2026
28 May · Results
28 May · Results
20 May · Board meeting
Meeting on 28 May 2026: audited results13 May · Meeting
12 May · Results
12 May · Meeting
11 May · ANNOUNCEMENT UNDER REGULATION 30
11 May · Announcement Under Regulation 30
11 May · Meeting
Apr 2026
6 Apr · Compliance-57 (5) : intimation after the end of quarter
6 Apr · COMPLIANCE CERTIFICATE UNDER REGULATION 7(3) FOR THE YEAR ENDED 31.03.2026
1 Apr · Meeting
1 Apr · Board meeting
Mar 2026
How the price met the news
The first session after each announcement, beside the market.
That dayThe first session's move. The first session's close after the announcement against the close before it, as a per cent change, on prices adjusted for splits and bonuses.Against the Nifty 500Against the Nifty 500. The share's move less the Nifty 500's move the same session, in percentage points (pts).Market median on that newsThe market's median move on that news. The middle first-session move of every listed company that filed the same kind of announcement, half moving more and half less.Five sessionsFive sessions' move. The close five sessions after the announcement against the close before it, as a per cent change.Five sessions against the Nifty 500Five sessions against the Nifty 500. The share's five-session move less the Nifty 500's move over the same five sessions, in percentage points (pts).Volume, times usualVolume, times usual. The session's shares traded divided by the average of the twenty sessions before it.
- 12 May 2026Board or managers changedup 2.19%+4.4 pts vs Nifty 500market median 0.0% · five sessions +0.2% (+1.7 pts vs Nifty 500) · volume 0.2× usual · The announcement
- 6 Jan 2026Board or managers changeddown 0.68%−0.5 pts vs Nifty 500market median 0.0% · five sessions −3.8% (−1.4 pts vs Nifty 500) · volume 0.1× usual · The announcement
- 1 Oct 2025Board or managers changed0.00%−0.9 pts vs Nifty 500market median 0.0% · five sessions −1.1% (−2.7 pts vs Nifty 500) · volume 0.1× usual · The announcement
- 6 Jun 2019Board or managers changedup 4.87%+5.7 pts vs Nifty 500market median 0.0% · five sessions +27.2% (+27.8 pts vs Nifty 500) · volume 0.4× usual · The announcement
- 23 May 2014Dividendup 4.81%+3.4 pts vs Nifty 500market median 0.0% · five sessions +15.8% (+16.6 pts vs Nifty 500) · volume 1.3× usual